Effect of probenecid on the distribution and elimination of ciprofloxacin in humans
- PMID: 7586947
- DOI: 10.1016/0009-9236(95)90173-6
Effect of probenecid on the distribution and elimination of ciprofloxacin in humans
Abstract
Objective: Probenecid-sensitive anion transport systems may be involved in distribution and elimination processes of anionic drugs. The aim of this study was to determine the effect of multiple probenecid treatment on the pharmacokinetic disposition of the zwitterionic fluoroquinolone ciprofloxacin in 12 healthy volunteers.
Methods: A single intravenous dose of 200 mg ciprofloxacin was given with and without multiple oral administration of probenecid in a randomized crossover fashion. Serial plasma, urine, saliva, tear, and sweat samples were drawn and analyzed for ciprofloxacin and its 2-aminoethylamino-metabolite (M1) by reversed-phase HPLC.
Results: Plasma area under the concentration-time curve and elimination half-life of ciprofloxacin were increased (p < 0.05), and urinary recovery and total and renal clearance decreased (p < 0.05) in the presence of probenecid. Nonrenal clearance and volume of distribution did not differ significantly with and without coadministration of probenecid. Peak plasma concentration, plasma area under the concentration-time curve, and elimination half-life of M1 were increased (p < 0.05) because of the higher amount of M1 formed and the reduced renal clearance (p < 0.05) of the metabolite. Saliva, tear, and sweat exposure were elevated (p < 0.05), but the alterations can be attributed primarily to the different kinetics of ciprofloxacin in plasma.
Conclusions: Coadministration of probenecid altered the renal excretion and hence the plasma concentrations of ciprofloxacin. Metabolite kinetics and distribution into saliva, tears, and sweat were affected accordingly, but there was no direct effect of probenecid on these processes. This type of drug-drug interaction might be of clinical relevance when ciprofloxacin is combined with drugs eliminated by the organic anion transport system in the kidney tubules.
Similar articles
-
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.Br J Clin Pharmacol. 2010 Feb;69(2):167-78. doi: 10.1111/j.1365-2125.2009.03564.x. Br J Clin Pharmacol. 2010. PMID: 20233180 Free PMC article. Clinical Trial.
-
Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid.Vet J. 2002 Jan;163(1):85-93. doi: 10.1053/tvjl.2001.0594. Vet J. 2002. PMID: 11749141
-
Effect of cimetidine and probenecid on pilsicainide renal clearance in humans.Clin Pharmacol Ther. 2000 Mar;67(3):222-8. doi: 10.1067/mcp.2000.104018. Clin Pharmacol Ther. 2000. PMID: 10741624 Clinical Trial.
-
Pharmacokinetics in the elderly. Studies on ciprofloxacin.Am J Med. 1987 Apr 27;82(4A):108-14. Am J Med. 1987. PMID: 3555025 Review.
-
Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.Am J Med. 1991 Dec 30;91(6A):51S-66S. doi: 10.1016/0002-9343(91)90312-l. Am J Med. 1991. PMID: 1662896 Review.
Cited by
-
Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.Antimicrob Agents Chemother. 2009 Sep;53(9):3902-7. doi: 10.1128/AAC.01200-08. Epub 2009 Jun 29. Antimicrob Agents Chemother. 2009. PMID: 19564368 Free PMC article. Clinical Trial.
-
Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.Pharm Res. 2015 Aug;32(8):2477-502. doi: 10.1007/s11095-015-1711-5. Epub 2015 May 14. Pharm Res. 2015. PMID: 25972096 Review.
-
Drug interactions at the renal level. Implications for drug development.Clin Pharmacokinet. 1998 May;34(5):375-404. doi: 10.2165/00003088-199834050-00004. Clin Pharmacokinet. 1998. PMID: 9592621 Review.
-
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.Br J Clin Pharmacol. 2010 Feb;69(2):167-78. doi: 10.1111/j.1365-2125.2009.03564.x. Br J Clin Pharmacol. 2010. PMID: 20233180 Free PMC article. Clinical Trial.
-
A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.Clin Pharmacokinet. 2018 Dec;57(12):1613-1634. doi: 10.1007/s40262-018-0661-6. Clin Pharmacokinet. 2018. PMID: 29737457 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources